SPARC and colorectal cancer: Moreover, we demonstrated that repressed SPARC expression in colorectal cancer cell lines resulting from aberrant hypermethylation, could be reversed following exposure to a demethylating agent, 5-Aza-2′deoxycytidine, which resulted in increased SPARC expression and enhanced sensitivity of colorectal cancer cells to 5-FU.